Unknown

Dataset Information

Considerations for transition from subcutaneous to oral prophylaxis in the treatment of hereditary angioedema.


ABSTRACT:

Background

Hereditary angioedema (HAE) is a rare genetic disorder characterized by unpredictable localized episodes of edema, which is frequently managed with long-term prophylactic medications. Until recently, long-term prophylaxis has predominantly required regular intravenous or subcutaneous administration, however the recent approval of berotralstat (Orladeyo™) offers an orally administered prophylactic which may be associated with a lower burden of treatment compared to injectable options for some patients.

Case presentation

This report describes four participants in the APeX-S trial who transitioned from subcutaneously administered lanadelumab (Takhzyro®) to daily oral berotralstat for long-term HAE prophylaxis. Lanadelumab dosing continued after berotralsta

SUBMITTER: Gower RG 

PROVIDER: S-EPMC8501591 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature